Status:
COMPLETED
Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Rosacea
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Rosacea is a frequent chronic inflammatory disease affecting mainly the face but also eyes and scalp. Rosacea is classified into 3 types: erythemato-teleangiectatica, papulopustulosa and phymatosa. Tr...
Eligibility Criteria
Inclusion
- Fitzpatrick skin type I-IV
- Presence of facial erythematous rosacea or mild papulopustular rosacea with permanent erythema
- Informed consent signed
Exclusion
- History of adverse events related to KTP laser therapy
- Pregnant or breastfeeding women
- Intention to become pregnant during the course of the study
- History of intolerance or allergic reaction to ivermectin 1% cream or one of the ingredients
- Ongoing treatment for skin cancer
- Ongoing treatment with strong inhibitors of P-glycoprotein (P-gp) and CYP3A4 (e.g., itraconazole, voriconazole, posaconazole, clarithromycin, cobicistat)
- Ongoing treatment with substances with a narrow therapeutic range whose excretion depends substantially on P-gp (e.g. digoxin, ciclosporin)
- Inability to understand the study content
Key Trial Info
Start Date :
September 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06033352
Start Date
September 12 2023
End Date
November 1 2024
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of dermatology, University Hospital Inselspital, Bern
Bern, Switzerland, 3010